Can Semaglutide Cause Blurry Vision — and When Should You Worry?

What the SUSTAIN-6 trial and prescribing information tell us

The clearest signal in the published data comes not from weight-management studies but from cardiovascular outcome trials in people with type 2 diabetes. The SUSTAIN-6 trial (a large randomised study of semaglutide in adults with established cardiovascular disease or high cardiovascular risk) recorded a higher rate of diabetic retinopathy complications in the semaglutide group compared with placebo: 3.0% versus 1.8%. This finding was significant enough to be carried forward into semaglutide's product information, and the NHS patient information for semaglutide lists diabetic retinopathy complications as an uncommon side effect requiring medical attention.

The mechanism most likely involved is the speed of glucose improvement. When blood sugar falls quickly, the lens of the eye can temporarily absorb fluid and change shape, producing blurriness that tends to settle over days to a few weeks. In people who already have fragile retinal blood vessels from longstanding diabetes, faster glucose reduction may also trigger retinal bleeding or swelling. This is not a reason to avoid treatment, but it is why prescribers ask carefully about diabetic eye disease before starting semaglutide, and why the SmPC advises ophthalmology monitoring for patients with a history of retinopathy. Our page on semaglutide and vision covers the full range of ocular considerations, including how these mechanisms play out across different patient groups.

For people without diabetes taking Wegovy purely for weight management, the absolute risk picture looks different: the STEP 1 trial (published in the New England Journal of Medicine) enrolled adults with obesity but without type 2 diabetes, and retinopathy complications were not identified as a notable finding in that cohort. That distinction matters, though it does not mean non-diabetic patients are completely unaffected by the glucose-related lens mechanism described above.

Does blurry vision from Wegovy go away on its own?

This is a question our prescribers hear most weeks, and the honest answer depends on which mechanism is driving it. The lens-swelling effect linked to early glucose shifts is generally self-limiting. Most people who notice mild blurring in the first few weeks of treatment find it settles without any intervention once the body adjusts to lower blood-sugar levels. Staying well-hydrated and keeping blood-sugar changes gradual (by titrating the dose slowly, as the prescriber intends) helps reduce the severity. For a deeper look at the typical timeline and what tends to distinguish temporary blurring from something requiring assessment, our page on whether blurred vision from Wegovy goes away covers that in detail.

Retinopathy-related changes are a different matter. If vision loss, floaters, or a dark area in your visual field develops, those are not symptoms to monitor at home. The NHS advises contacting a clinician the same day for any sudden vision change. A prescriber can arrange urgent ophthalmology review, and if needed, pause or adjust treatment while the eye is assessed. The key point is that early intervention almost always leads to better outcomes than waiting.

Separately, some people find that changing their prescription glasses feels overdue when they start semaglutide, this is usually the lens-swelling effect rather than permanent change to eyesight, and opticians generally advise waiting until blood-sugar levels have been stable for at least a few weeks before updating a glasses prescription.

Who carries the most risk, and what your prescriber looks for

The risk profile is not uniform. People most likely to notice vision-related effects include those who had elevated blood sugar before starting treatment, anyone with a pre-existing diagnosis of diabetic retinopathy, and those whose dose is increased quickly. During the clinical assessment that precedes any prescription, a GPhC-registered prescriber will ask about eye health, current diabetes status and any history of retinal problems, this is part of why a thorough clinical review matters before these medicines are prescribed. Semaglutide is a prescription-only medicine that requires individual assessment; the consultation is where this safety check happens.

For context on how semaglutide (as Wegovy) fits into the wider landscape of licensed UK weight-management treatments, the Wegovy overview page explains the UK licence, the titration schedule and the full side-effect profile in one place. Anyone who has had laser eye treatment for retinopathy, or who is currently under ophthalmology review for any diabetic eye complication, should flag this explicitly during their consultation. The MHRA's Yellow Card scheme at yellowcard.mhra.gov.uk is the right channel for reporting any suspected side effect, including visual symptoms, once treatment has started, whether or not it turns out to be related.

If you are considering semaglutide and want to understand how Wegovy can affect vision across different circumstances, that page addresses the topic from a broader clinical angle. And if you are weighing up the cost of a private prescription as part of your decision, the Wegovy price page sets out what private treatment typically involves. When you are ready to speak with a prescriber about whether semaglutide is appropriate for you, you can start your free consultation with the nume clinical team.